Inpatient: Patients with relapsed/refractory multiple myeloma for the initial step-up dosing cycle only; restricted to hematology service. Consider subsequent repeat step-up doses as non-formulary with case-by-case evaluation. Secure payor authorization for the medication and the admission, prior to drug procurement and patient admission.
Outpatient: Defer to payor clinical criteria.
The goal of the Tecvayli and Talvey REMS program is to mitigate the risks of cytokine release syndrome (CRS) and neurologic toxicity including immune effector cell-associated neurotoxicity (ICANS), and includes healthcare provider, patient, pharmacy and wholesaler-distributor requirements for dispensing.
Add Formweb to your mobile device
Formulary restriction
Inpatient: Patients with relapsed/refractory multiple myeloma for the initial step-up dosing cycle only; restricted to hematology service. Consider subsequent repeat step-up doses as non-formulary with case-by-case evaluation. Secure payor authorization for the medication and the admission, prior to drug procurement and patient admission.
Outpatient: Defer to payor clinical criteria.
The goal of the Tecvayli and Talvey REMS program is to mitigate the risks of cytokine release syndrome (CRS) and neurologic toxicity including immune effector cell-associated neurotoxicity (ICANS), and includes healthcare provider, patient, pharmacy and wholesaler-distributor requirements for dispensing.
See Legacy Health REMS Requirements for detail.